|Full HTA Assessment
|Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia.
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended.
We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.